Advances in the Application of Engineered Exosomes in the Treatment of Drug Resistance in Gynecological Tumors

doi:10.12280/gjfckx.20230767

Abstract

Abstract:

Gynecological malignant tumor is a serious threat to women's health, with high morbidity and mortality among various female diseases. The key reason lies in the inadequate curative effect of traditional chemotherapy on relapsed and drug-resistant patients. In recent years, to explore the mechanism of chemotherapy resistance of tumor cells and to develop new chemotherapy reversal agents has become a focus of gynecological cancer researchers. Exosomes are a kind of multivesicular bodies originated from the formation of intracellular lysosomal particle invaginations, with biological properties such as low immunogenicity, innate targeting and acquired targeting, and high delivery efficiency. Therefore, exosomes can be used as an ideal, natural nanocarriers for drug delivery, which can not only reduce tumor resistance to chemotherapy drugs, improving the therapeutic effect of drugs, but also reduce the toxic and side effects of chemotherapy drugs on the whole body. This review summarizes the research progress of exosomes as drug carriers in drug-resistant treatment of gynecological tumors in order to to providing assistance in the clinical treatment of gynecological tumors.

Key words: Exosomes, Genital neoplasms, female, Drug resistance, neoplasm, Drug carriers, Molecular targeted therapy

GUO Xin, ZHANG Jian-nan, GUO Nan, NING Wen-ting, SHANG Hai-xia. Advances in the Application of Engineered Exosomes in the Treatment of Drug Resistance in Gynecological Tumors[J]. Journal of International Obstetrics and Gynecology, 2024, 51(1): 42-46.

References 32

[1]	Moon B, Chang S. Exosome as a Delivery Vehicle for Cancer Therapy[J]. Cells, 2022, 11(3):316. doi: 10.3390/cells11030316.
[2]	Zhou Y, Zhang Y, Gong H, et al. The Role of Exosomes and Their Applications in Cancer[J]. Int J Mol Sci, 2021, 22(22):12204. doi: 10.3390/ijms222212204.
[3]	Munagala R, Aqil F, Jeyabalan J, et al. Bovine milk-derived exosomes for drug delivery[J]. Cancer Lett, 2016, 371(1):48-61. doi: 10.1016/j.canlet.2015.10.020. pmid: 26604130
[4]	王华. 间充质干细胞及其来源的胞外囊泡[J]. 中国生物化学与分子生物学报, 2023, 39(3):354-363. doi: 10.13865/j.cnki.cjbmb.2022.10.1354.
[5]	Meng W, He C, Hao Y, et al. Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source[J]. Drug Deliv, 2020, 27(1):585-598. doi: 10.1080/10717544.2020.1748758. pmid: 32264719
[6]	Roy A, Girija As S, Sankar Ganesh P, et al. Exosome Mediated Cancer Therapeutic Approach: Present Status and Future Prospectives[J]. Asian Pac J Cancer Prev, 2023, 24(2):363-373. doi: 10.31557/APJCP.2023.24.2.363.
[7]	Zhong J, Xia B, Shan S, et al. High-quality milk exosomes as oral drug delivery system[J]. Biomaterials, 2021, 277:121126. doi: 10.1016/j.biomaterials.2021.121126.
[8]	Kandimalla R, Aqil F, Tyagi N, et al. Milk exosomes: A biogenic nanocarrier for small molecules and macromolecules to combat cancer[J]. Am J Reprod Immunol, 2021, 85(2):e13349. doi: 10.1111/aji.13349.
[9]	Timofeeva AM, Paramonik AP, Sedykh SS, et al. Milk Exosomes: Next-Generation Agents for Delivery of Anticancer Drugs and Therapeutic Nucleic Acids[J]. Int J Mol Sci, 2023, 24(12):10194. doi: 10.3390/ijms241210194.
[10]	Peng H, Ji W, Zhao R, et al. Exosome: a significant nano-scale drug delivery carrier[J]. J Mater Chem B, 2020, 8(34):7591-7608. doi: 10.1039/d0tb01499k. pmid: 32697267
[11]	Zhao X, Wu D, Ma X, et al. Exosomes as drug carriers for cancer therapy and challenges regarding exosome uptake[J]. Biomed Pharmacother, 2020, 128:110237. doi: 10.1016/j.biopha.2020.110237. pmid: 32470747
[12]	Xi XM, Xia SJ, Lu R. Drug loading techniques for exosome-based drug delivery systems[J]. Pharmazie, 2021, 76(2):61-67. doi: 10.1691/ph.2021.0128.
[13]	Elsharkasy OM, Nordin JZ, Hagey DW, et al. Extracellular vesicles as drug delivery systems: Why and how?[J]. Adv Drug Deliv Rev, 2020, 159:332-343. doi: 10.1016/j.addr.2020.04.004.
[14]	Mulcahy LA, Pink RC, Carter DR. Routes and mechanisms of extracellular vesicle uptake[J]. J Extracell Vesicles, 2014 Aug 4;3. doi: 10.3402/jev.v3.24641.
[15]	郝东霞, 田梦园, 刘洋, 等. 乳外泌体的基本性质及其应用[J]. 中国生物工程杂志, 2023, 43(2):26-42. doi: 10.13523/j.cb.2210010.
[16]	Zhang Y, Li J, Gao W, et al. Exosomes as Anticancer Drug Delivery Vehicles: Prospects and Challenges[J]. Front Biosci(Landmark Ed), 2022, 27(10):293. doi: 10.31083/j.fbl2710293.
[17]	张琪, 于湄, 刘磊, 等. 工程化外泌体研究现状与临床转化的挑战[J]. 中国组织工程研究, 2023, 27(19):3052-3060.
[18]	Rajput A, Varshney A, Bajaj R, et al. Exosomes as New Generation Vehicles for Drug Delivery: Biomedical Applications and Future Perspectives[J]. Molecules, 2022, 27(21):7289. doi: 10.3390/molecules27217289.
[19]	Chen Q, Shi J, Ruan D, et al. The diagnostic and therapeutic prospects of exosomes in ovarian cancer[J]. BJOG, 2023, 130(9):999-1006. doi: 10.1111/1471-0528.17446.
[20]	Melzer C, Ohe JV, Hass R. Anti-Tumor Effects of Exosomes Derived from Drug-Incubated Permanently Growing Human MSC[J]. Int J Mol Sci, 2020, 21(19):7311. doi: 10.3390/ijms21197311.
[21]	Qiu L, Wang J, Chen M, et al. Exosomal microRNA-146a derived from mesenchymal stem cells increases the sensitivity of ovarian cancer cells to docetaxel and taxane via a LAMC2-mediated PI3K/Akt axis[J]. Int J Mol Med, 2020, 46(2):609-620. doi: 10.3892/ijmm.2020.4634.
[22]	Aqil F, Jeyabalan J, Agrawal AK, et al. Exosomal delivery of berry anthocyanidins for the management of ovarian cancer[J]. Food Funct, 2017, 8(11):4100-4107. doi: 10.1039/c7fo00882a. pmid: 28991298
[23]	Zhang X, Liu L, Tang M, et al. The effects of umbilical cord-derived macrophage exosomes loaded with cisplatin on the growth and drug resistance of ovarian cancer cells[J]. Drug Dev Ind Pharm, 2020, 46(7):1150-1162. doi: 10.1080/03639045.2020.1776320. pmid: 32482115
[24]	Luo H, Zhou Y, Zhang J, et al. NK cell-derived exosomes enhance the anti-tumor effects against ovarian cancer by delivering cisplatin and reactivating NK cell functions[J]. Front Immunol, 2022, 13:1087689. doi: 10.3389/fimmu.2022.1087689.
[25]	Abas BI, Demirbolat GM, Cevik O. Wharton jelly-derived mesenchymal stem cell exosomes induce apoptosis and suppress EMT signaling in cervical cancer cells as an effective drug carrier system of paclitaxel[J]. PLoS One, 2022, 17(9):e0274607. doi: 10.1371/journal.pone.0274607.
[26]	Aqil F, Munagala R, Jeyabalan J, et al. Exosomes for the Enhanced Tissue Bioavailability and Efficacy of Curcumin[J]. AAPS J, 2017, 19(6):1691-1702. doi: 10.1208/s12248-017-0154-9. pmid: 29047044
[27]	Abbasifarid E, Bolhassani A, Irani S, et al. Synergistic effects of exosomal crocin or curcumin compounds and HPV L1-E7 polypeptide vaccine construct on tumor eradication in C57BL/6 mouse model[J]. PLoS One, 2021, 16(10):e0258599. doi: 10.1371/journal.pone.0258599.
[28]	常筱晗. 外泌体在子宫内膜癌诊断及治疗中的研究进展[J]. 中国微创外科杂志, 2023, 23(4):303-307. doi: 10.3969/j.issn.1009-6604.2023.04.013.
[29]	Bogaczyk A, Zawlik I, Zuzak T, et al. The Role of miRNAs in the Development, Proliferation, and Progression of Endometrial Cancer[J]. Int J Mol Sci, 2023, 24(14):11489. doi: 10.3390/ijms241411489.
[30]	Li BL, Lu W, Qu JJ, et al. Loss of exosomal miR-148b from cancer-associated fibroblasts promotes endometrial cancer cell invasion and cancer metastasis[J]. J Cell Physiol, 2019, 234(3):2943-2953. doi: 10.1002/jcp.27111.
[31]	Zhou WJ, Zhang J, Xie F, et al. CD45RO^-CD8⁺ T cell-derived exosomes restrict estrogen-driven endometrial cancer development via the ERβ/miR-765/PLP2/Notch axis[J]. Theranostics, 2021, 11(11):5330-5345. doi: 10.7150/thno.58337.
[32]	Qian T, Yu X, Xu A, et al. tRF-20-S998LO9D inhibits endometrial carcinoma by upregulating SESN2[J]. Epigenomics, 2022, 14(24):1563-1577. doi: 10.2217/epi-2022-0349. pmid: 36803014